UPDATE 1-NicOx says makes progress on two drug candidates

* Two drug candidates moved to preclinical data phase

* NCX 434 for diabetic macular edema, N1236 for pain

* Preclinical data presented at scientific conferences

(Adds details from statement, writes through)

PARIS, June 1 (BestGrowthStock) – French biotechnology group NicOx
(NCOX.PA: ) said two new drug candidates had moved into the
preclinical research phase, with preclinical data presented at
scientific conferences for the first time.

NicOx said the two drug candidates were NCX 434, a
preclinical candidate in diabetic macular edema, and NC 1236, a
preclinical lead compound for neuropathic pain.
Earlier this month NicOx shares slumped after a U.S. panel
rejected the company’s pain drug naproxcinod, its greatest hope.
[ID:nLDE64C05Z] The company’s CEO Michele Garufi said he
remained confident of naproxcinod’s medical value.

NicOx’s business is based around the idea that nitric
oxide-releasing versions of established medicines, such as
naproxcinod, can offer significant benefits over the original —
for example, by lowering blood pressure risk.

NicOx shares closed 5.08 percent higher on Monday before the
latest announcement.

Stock Market Advice

(Reporting by Helen Massy-Beresford; Editing by Louise Heavens)

UPDATE 1-NicOx says makes progress on two drug candidates